Magnetic stimulation aids in suppressing auditory hallucinations in individuals with schizophrenia
Transcranial Magnetic Stimulation (TMS), a non-invasive neurostimulation technique, is emerging as a potential alternative treatment for schizophrenia, particularly targeting cognitive impairments and negative symptoms. This technique, which has been FDA-approved for treating depression and other psychiatric disorders, uses electromagnetic pulses to modulate brain activity in targeted regions.
Recent research includes protocols like individualized transcranial temporal interference stimulation (tTIS), a variant of TMS, aimed at improving cognitive dysfunction and negative symptoms common in schizophrenia. Although the definitive clinical outcomes are not yet published, ongoing investigation in this area is promising.
A large clinical study conducted at seven university psychiatric clinics in Germany has provided the first evidence that TMS is an effective and safe treatment option for people who hear voices due to schizophrenia. The study, led by the University Hospital of Tuebingen, was published in the journal The Lancet Psychiatry.
The treatment, which alters brain activity using an electrical coil and delivers a series of magnetic impulses from outside the head, specifically targeting brain areas responsible for language and speech processing, has shown a lasting effect for some patients. A 29-year-old schizophrenia patient reported feeling relief from voices after three or four days of treatment, describing the therapy as painless and feeling like a tapping on the head, with certain parts of the face moving a bit.
The daily stimulation helps to restore the balance of brain activity that normally prevents hearing voices or experiencing depression. The therapy with magnetic stimulation is precise and low in side effects. TMS has been tested for over a decade on 138 adults who all suffered from treatment-resistant auditory hallucinations associated with schizophrenia. For three weeks, participants received either 15 sessions of real magnetic stimulation or a sham treatment (placebo). The treatment with TMS resulted in a significant improvement for the participants.
While TMS is funded by statutory health insurers for depression treatment in inpatient settings, outpatient treatment remains with private insurers. Work is underway to include TMS in clinical guidelines. A comprehensive clinical study on the treatment of severe depression with TMS is due to be completed by the end of the year.
The challenge remains to make TMS treatment more accessible to all affected individuals. The scientific evidence provided by the large multicenter, randomized clinical trial should have consequences, according to Christian Plewnia. The potential implications include future long-term treatment protocols and combined cognitive therapies, but conclusive evidence and clinical guidelines specific to schizophrenia are still under development.
TMS is already being successfully used in other conditions such as tinnitus. The emerging potential of TMS as an alternative treatment for schizophrenia, especially targeting cognitive impairments and negative symptoms, highlights the need for further research and the development of more rigorous clinical trials to establish its effectiveness and optimize protocols.
- The emerging potential of Transcranial Magnetic Stimulation (TMS) as an alternative treatment for neurological disorders such as schizophrenia is highlighted by its effectiveness in targeting cognitive impairments and negative symptoms.
- Medical-conditions like schizophrenia, which are often resistant to traditional treatments, may benefit from health-and-wellness therapies and treatments like Transcranial Magnetic Stimulation (TMS), as indicated by recent studies.
- In the realm of science, advancements in Transcranial Magnetic Stimulation (TMS) technologies, such as individualized transcranial temporal interference stimulation (tTIS), are being explored for their potential in addressing medical-conditions like schizophrenia and improving health-and-wellness outcomes for patients.
